1.Process of recovery of M. soleus atrophy in rabbit after Immobilization, with special reference to structural and soluble proteins.
TOMOKAZU ITO ; YOSHIHIRO WATANABE ; YOSHIHIKO OHSHIMA
Japanese Journal of Physical Fitness and Sports Medicine 1993;42(4):360-370
Previous studies have shown that the process of recovery after disuse muscle atrophy varies in different experimental models. We investigated the process of recovery of M, soleus atrophy after immobilization, with special reference to changes in structural and soluble proteins by means of electrophoresis and histochemical changes using myosin-ATPase staining. After rabbits had been subjected to 3 weeks of hindlimb immobilization, the changes were investigated immediately after the termination of immobilization, and at 1, 2, 3, 4 and 6 weeks of recovery. Just after the termination of immobilization, the wet weight of the M. soleus was 32.7±14.0% that of the opposite limb. The wet weight recovered rapidly and returned to the same level as that of the opposite side by 4 weeks. The amount of structural proteins decreased after immobilization, but did not return to the control level at 6 weeks after recovery. No new bands appeared in the electrophoretic patterns of the structural and soluble proteins at any of the stages of recovery. Furthermore, the special features of the bands of myosin light chains (MLCs-1, MLCs-2) also showed no change. ATPase staining showed that the area of type 2 fibers increased, and occupied 45.2±12.6% of the total area at 3 weeks after recovery, whereas that of muscle from controls occupied 17.3±5.7%. The area did not return too the control level by 6 weeks of recovery. The discrepancy between the histochemical changes and the changes in structural or soluble proteins during the recovery process appeared to be due to differences in the turnover ratio of each protein. It appears that the process of recovery of disuse muscle atrophy after immobilization is variable and compley, and differs according to the method of observation.
2.A Trial of Objective Measurement of Pain
Isao MATSUMOTO ; Yoshihiko WATANABE ; Kuninori YOKOYAMA ; Etsutaro IKEZONO ; Haruo SANO
Journal of the Japan Society of Acupuncture and Moxibustion 1982;32(1):5-9
Introduction
We attempted to get an objective index of pain, giving electro-nocistimulus to the tooth and making a comparison between the stimulus rate and subjective pain. We examined variations of the response to stimulus under this low-frequency electric treatment.
Method
Treated were single healthy upper incisors of 14 medical doctors. Fixing a silver electrode of 4mm2 on each tooth and an indifferent electrode on the buccal surface of the same side, stimulation was applied.
Effect
Three categories of pain, i. e. pre-pain, tolerable pain and intolerable pain were established for the purpose of this study. We made use of these categories as an objective index of pain. It was also evident that, under low frequency electric treatment to acupoints of acupuncture anesthesia, there were variations in intolerable pain. We examined variations of this pain.
Conclusion
It was concluded that there were two types of objects, i. e. the effective and the ineffective.
Intolerable level was affected by the low frequency electric treatment and pain was alleviated.
3.Effects of Electroacupuncture on the Levels of Endorphins and Substance P in Lumbar CSF
Shinobu Nakano ; Atsushi Niimura ; Yoshihiko Watanabe ; Isao Matsumoto ; Etsutaro Ikezono
Journal of the Japan Society of Acupuncture and Moxibustion 1981;31(2):146-150
The pain eliminating effects of electroacupuncture have long been known however the analgesic mechanism involved has yet to be clarified. Recently with the discovery of endogenous analgesic peptids called endorphins much attention has been called to the relationship of these endorphins and the acupuncture analgesic effect. We examined to determine how electroacupuncture influences lumbar CSF endorphins and the so-called pain transmitting substance, Substance P.
In order to establish continuous lumbar anesthesia using tetracaine for 8 patients with gynecological lower abdominal diseases, a Tuohy needle was inserted from the lumbar area and a catheter inserted into the subarachnoidal space. In each case at the time of the insertion of the catheter 5ml. CSF was tapped. As pre-medication 0.01mg/kg. atropine sulfate, 2mg/kg secobarbiturate were administered. To maintain the analgesic effect hyperbaric or hypobaric tetracaine was administered according to individaul needs. For hypotension during the operations a plasma expander and when necessary ephedrine were administered by intramuscular or intravenous injection.
Immediately following the start of surgery acupuncture needles were inserted at right and left LI-4 and electrical stimulation at 3c/s, 1.0mA was administered for 50-120 minutes using the acupuncture therapy apparatus “TOKKI”. when the operation was finished, after 5ml. of CSF was again tapped through the catheter, the catheter was withdrawn as far as the subdural space and 20-40ml. physiological saline injected to combat the headache due to spinal fluid leakage. The test substance was immediately transferred to a siliconized test tube and cooled to a temperature of-80°C.
The RIA methods were used for the measurement of both endorphins and substance P. The crossover reaction between the β-endorphin and the βLPH was 50%. (Using the β-endorphin measuring kit manufactured by NEN).
The results in 7 of 8 examples showed a significant increase in CSF endorphins after electroacupuncture. It also became clear that there was a tendency for substance P levels to decrease due to electroacupuncture.
4.Study of Efficacy and Safety in the Administration of 400 mg of Amikacin Sulfate Administered Once Daily to Elderly Patients
Yoshihiko Matsuki ; Tetsuya Tsukamoto ; Makoto Hosoyamada ; Tamaki Watanabe ; Shigekazu Watanabe ; Masao Tsuchiya
Japanese Journal of Drug Informatics 2013;15(2):51-56
Objective: In previously reported comparisons of aminoglycoside antimicrobials administered once daily versus multiple administration, toxicity was found to be equal or lower while efficiency remained high. However, there are few reports on the clinical condition of targeted elderly persons. The objective of this study was to evaluate the once-daily dosing regimen of 400 mg of AMK involving elderly pneumonia patients aged 75 years or older with regard to clinical evaluation including the efficacy and toxicity.
Methods: A survey to clinically evaluate the efficacy and toxicity of 400 mg AMK administered once daily for 30 min at 24 h intervals was carried out. One hundred twenty-seven patients with pneumonia and who were 75 years or older at Funabashi General Hospital were targeted, with the aim of an expected clinical effect of Cmax/MIC≥ 8-10. Serum concentration monitoring was carried out after administration began.
Results: There were 121 patients (95.3%) of controlled AMK concentration with a trough serum concentration of <10 μg/mL, which is a safe concentration range. There were 6 patients (4.7%) where trough serum concentration in the toxic range >10 μg/mL, with an average at 15.1±5.0 μg/mL, and the average administration days were 7.5 ± 3.3 days. Moreover, before/after AMK administration, there were 3 patients (2.4%) where CRE values increased more than a 150% over the previous values, and were evaluated as renal dysfunction. Average trough serum concentration at that time was 3.6 ± 1.1 μg/mL, and average number of days of administration were 13 ± 1.4 days. Patients of trough serum concentration in the toxic range >10 μg/mL were not included. The average peak serum concentration calculated by Winter’s pharmacokinetic parameter and the 1-compartment model was 35.3 ± 8.0 μg/mL, and the average Cmax/MIC which correlates with the AMK effect was 9.9 ± 2.2. The treatment was effective for 83 (65.4%) of the 127 patients.
Conclusion: By once-daily administration of AMK 400 mg to aged persons 75 years or older, change in trough serum concentration into a safe range and Cmax/MIC≥ 8-10, the level at which clinical effectivity can be expected, could be achieved. This administration method is shown to be useful in maintaining AMK in the target serum concentration range for aged persons.
5.A Successful Case of Treatment of Graft Infection by Using Allografts after Ascending Thoracic Aortic Reconstruction
Tomohiro Nakajima ; Noriyasu Watanabe ; Satoshi Muraki ; Kazushige Kanki ; Yoshihiko Kurimoto ; Tetsuya Higami
Japanese Journal of Cardiovascular Surgery 2010;39(3):155-158
Thoracic graft infection is a serious complication and has high mortality. We report a case of successful treatment of graft infection after ascending thoracic aortic reconstruction. A 66-year-old woman underwent surgery for DeBakey type I aortic dissection in June 2007. The ascending aorta was replaced with a prosthetic graft. Although her postoperative course was complicated with Methicillin-resistant Staphylococcus aureus (MRSA) mediastinitis, the infection was conservatively controlled by mediastinal lavage and antibiotics. However, she was readmitted in April 2008 due to lumbar pain and high fever, and was diagnosed with infectious spondylitis. Lumbar plastic surgery was performed. During hospitalization, she underwent total systemic examination. The results indicated aneurysm of the ascending aorta. MRSA was detected from culture fluid of her blood. Taken together, the presence of an infected aortic aneurysm was considered possible. Consequently, reconstruction of the ascending aorta using two allografts was performed after removing the prosthetic graft. The postoperative course was uneventful, and she was discharged on the 71st postoperative day. The patient continues to thrive 9 months after the operation. This case of an infected aortic aneurysm repaired with the use of allografts will be reported together with references to the literature.
6.Efficacy and safety of fentanyl patch in cancer patients from the active treatment period to the terminal stage
Norio Watanabe ; Mikio Yasumura ; Naomasa Yoshida ; Yoshihiko Kato ; Chigusa Nakagawa ; Ken-ichiro Tateyama ; Keiko Yamamura ; Kimio Yasuda
Palliative Care Research 2008;3(1):E1-E2
A correction of a coauthor's name from Chigusa Nakamura to Chigusa Nakagawa on the author list and the abstract.
7.Efficacy and safety of fentanyl patch in cancer patients from the active treatment period to the terminal stage
Norio Watanabe ; Mikio Yasumura ; Naomasa Yoshida ; Yoshihiko Kato ; Chigusa Nakamura ; Ken-ichiro Tateyama ; Keiko Yamamura ; Kimio Yasuda
Palliative Care Research 2008;3(1):201-208
Purpose: From shortly after the fentanyl patch became commercially available, we have been using it as part of our armamentarium for cancer therapy to produce a reliable analgesic effect from the active treatment period to the terminal stage in patients who are expected to develop resistance to oral analgesics. To confirm the usefulness of fentanyl patch, a retrospective study was conducted to determine its efficacy and safety. Method: A survey was conducted of 28 cancer patients who were undergoing pharmacological pain control. The following parameters were recorded: opioids administered prior to fentanyl patch use, reasons for switching to fentanyl patch, duration of administration and dosage of fentanyl patch, pain score before switching to fentanyl patch, adverse effects (nausea, vomiting, constipation and drowsiness), and the results of clinical tests. Results: The major reasons for switching to fentanyl patch were: "pain control with oral agents was expected to become difficult in future" and "adverse effects of chemotherapy were noted or were likely to develop". The mean duration of fentanyl patch use was 133 days, during which time the pain score and the constipation symptom were significantly reduced. No significant difference was found with nausea, vomiting, drowsiness or the results of clinical tests. Conclusion: It is concluded that fentanyl patch is a highly useful opioid for analgesia when administered during chemotherapy for cancer and continued to the terminal stage.
8.Evaluation of a Novel Glucose Area Under the Curve (AUC) Monitoring System: Comparison with the AUC by Continuous Glucose Monitoring.
Satoshi UGI ; Hiroshi MAEGAWA ; Katsutaro MORINO ; Yoshihiko NISHIO ; Toshiyuki SATO ; Seiki OKADA ; Yasuo KIKKAWA ; Toshihiro WATANABE ; Hiromu NAKAJIMA ; Atsunori KASHIWAGI
Diabetes & Metabolism Journal 2016;40(4):326-333
BACKGROUND: Management of postprandial hyperglycemia is a key aspect in diabetes treatment. We developed a novel system to measure glucose area under the curve (AUC) using minimally invasive interstitial fluid extraction technology (MIET) for simple monitoring of postprandial glucose excursions. In this study, we evaluated the relationship between our system and continuous glucose monitoring (CGM) by comparing glucose AUC obtained using MIET with that obtained using CGM for a long duration. METHODS: Twenty diabetic inpatients wearing a CGM system were enrolled. For MIET measurement, a plastic microneedle array was applied to the skin as pretreatment, and hydrogels were placed on the pretreated area to collect interstitial fluid. Hydrogels were replaced every 2 or 4 hours and AUC was predicted on the basis of glucose and sodium ion levels. RESULTS: AUC predicted by MIET correlated well with that measured by CGM (r=0.93). Good performances of both consecutive 2- and 4-hour measurements were observed (measurement error: 11.7%±10.2% for 2 hours and 11.1%±7.9% for 4 hours), indicating the possibility of repetitive measurements up to 8 hours. The influence of neither glucose fluctuation nor average glucose level over the measurement accuracy was observed through 8 hours. CONCLUSION: Our system showed good relationship with AUC values from CGM up to 8 hours, indicating that single pretreatment can cover a large portion of glucose excursion in a day. These results indicated possibility of our system to contribute to convenient monitoring of glucose excursions for a long duration.
Area Under Curve*
;
Extracellular Fluid
;
Glucose*
;
Humans
;
Hydrogel
;
Hydrogels
;
Hyperglycemia
;
Inpatients
;
Plastics
;
Skin
;
Sodium
9.Measurement of Hymenoptera venom specific IgE by the IMMULITE 3gAllergy in subjects with negative or positive results by ImmunoCAP
Mineaki WATANABE ; Hirokuni HIRATA ; Masafumi ARIMA ; Yumeko HAYASHI ; Kazuyuki CHIBANA ; Naruo YOSHIDA ; Yoshihiko IKENO ; Yasutsugu FUKUSHIMA ; Reiko KOMURA ; Kazumi OKAZAKI ; Kumiya SUGIYAMA ; Takeshi FUKUDA
Asia Pacific Allergy 2012;2(3):195-202
BACKGROUND: Patients may receive negative results from a specific IgE (sIgE) test such as the ImmunoCAP (CAP) despite a documented history of systemic reaction to a Hymenoptera sting. Thus, further testing may be required using another serological method or venom skin prick tests to confirm allergy diagnosis and correct species. OBJECTIVE: To evaluate the sensitivity and the specificity of CAP and IMMULITE 3gAllergy (IMMULITE) for detecting sIgE to Paper wasp (WA) and Yellow Jacket (YJ) venoms using patient clinical history as the comparator. METHODS: Sera from 70 participants with a history of systemic reactions (SR) to WA and/or YJ stings were tested using CAP and IMMULITE. Fifty participants from this group had negative results on CAP. To assess specificity, sera from 71 participants who had never experienced either a WA or YJ sting were tested using CAP and IMMULITE. Fifty participants from this group tested positive using CAP. RESULTS: In participants with a history of systemic reaction to a Hymenoptera sting, yet who tested negative for WA and/or YJ sIgE according to CAP, the positivity rate according to IMMULITE was 20-42% using 0.10 IUA/mL as the limit of detection (LoD), per the manufacturer's specification. When the LoD for CAP (0.35 IUA/mL) was applied to the IMMULITE results, positivity according to IMMULITE was 14-26%. Overall, sensitivity, specificity, and agreement with SR were greater for IMMULITE than for CAP. For YJ: sensitivity (IMMULITE:CAP), 42.8%:28.5%; specificity, 53.5%:39.4%; agreement, 48.2%:34%. For WA, sensitivity (IMMULITE:CAP), 58.6%:28.5%; specificity, 49.3%:47.8%; agreement, 43.9%:38.3%. CONCLUSION: The IMMULITE performed well for detecting sIgE to Hymenoptera venom
Bites and Stings
;
Diagnosis
;
Humans
;
Hymenoptera
;
Hypersensitivity
;
Immunoglobulin E
;
Limit of Detection
;
Methods
;
Sensitivity and Specificity
;
Skin
;
Venoms
;
Wasps
10.Erratum: Measurement of Hymenoptera venom specific IgE by the IMMULITE 3gAllergy in subjects with negative or positive results by ImmunoCAP
Mineaki WATANABE ; Hirokuni HIRATA ; Masafumi ARIMA ; Yumeko HAYASHI ; Kazuyuki CHIBANA ; Naruo YOSHIDA ; Yoshihiko IKENO ; Yasutsugu FUKUSHIMA ; Reiko KOMURA ; Kazumi OKAZAKI ; Kumiya SUGIYAMA ; Takeshi FUKUDA
Asia Pacific Allergy 2013;3(1):74-74
We would like to report the following errata in Table 4, and request that these items be revised appropriately.